Common variable immunodeficiency (CVID) is a form of primary immunodeficiency that results from impaired B-cell secretion of immunoglobulins. Patients with CVID have an increased susceptibility to recurrent and chronic infections and also an increased incidence of autoimmune and lymphoproliferative disorders and cancer. A 33- year old male patient has been followed-up with the diagnosis of CVID and from early childhood he experienced recurrent respiratory infections. In January 2010, patient was admitted in GH with the symptoms of bronchopneumonia and during disease evaluation he was diagnosed with CVID. According to the guidelines, patient was treated with substitute IV immunoglobulins. During follow-up in day care and stationary UHC departments (2011 - 2020), patient experienced in total 14 respiratory (7 pneumonias, 5 acute sinusitides, 2 acute exacerbations of chronic bronchitis) and 2 digestive system (chronic gastritis, colitis) complications of CVID. Lastly, he developed noninfectious pulmonary complication - granulomatous-lymphocytic interstitial lung disease (GLILD). In 2015, CVID treatment was modified in order to accomplish satisfactory IG levels. Therefore, patient was transferred from IV to conventional IGSC therapy. Due to easier application and greater volume of SC inserted IG, patient was switched to new generation IGSC therapy in 2019. Besides that, corticosteroides and mesalazine were also administered and with current treatment patient is stable. Although respiratory infections are common CVID complications it is also necessary to consider the autoimmune and neoplastic manifestations of the disease. Multidisciplinary approach, regular follow-up and application of immunoglobulins are the key factors in decreasing the disability and mortality in patients with CVID.